Zobrazeno 1 - 8
of 8
pro vyhledávání: '"David H. Adams"'
Publikováno v:
THURSDAY, 14 JUNE 2018.
Background Ixekizumab (IXE) is a high-affinity monoclonal antibody selectively targeting interleukin-17A. Compared to placebo (PBO), IXE resulted in significantly greater reduction and clearance of fingernail and skin lesions at Wk 24 in patients (pt
Autor:
P. J. Mease, Peter Nash, Sandra Garces, Olivier Bénichou, Euthalia Roussou, Gerd-Rüdiger Burmester, Wen Xu, Philippe Goupille, Alice B. Gottlieb, David H. Adams
Publikováno v:
Saturday, 16 JUNE 2018.
Background Ixekizumab (IXE), a high affinity monoclonal antibody that selectively targets interleukin-17A, has been shown to be superior to placebo (PBO) in improving signs and symptoms of psoriatic arthritis (PsA) in Phase 3 trials1, 2. Objectives T
Autor:
A. Deodhar, Ana Maria Orbai, Peter Nash, Olivier Bénichou, S. Rathmann, Frank Behrens, David H. Adams
Publikováno v:
Psoriatic arthritis.
Background Registry studies1,2 suggest that cDMARDs do not improve TNFi efficacy in the treatment of psoriatic arthritis (PsA), but studies of novel biologics are warranted. In SPIRIT-P2, TNFi-experienced patients with active PsA were treated with ix
Publikováno v:
Saturday, 16 JUNE 2018.
Background Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. In patients with active psoriatic arthritis (PsA) who had an inadequate response to tumour necrosis factor inhibitors (TNFi), IXE was superio
Publikováno v:
Poster Presentations.
Background Ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting interleukin-17A, significantly improved fingernail psoriasis by Week (Wk) 12 vs placebo (PBO) in patients (pts) with moderate-to-severe plaque psoriasis 1 . Moreov
Autor:
Olivier Bénichou, P S Helliwell, Eric Lespessailles, Lisa Kerr, David H. Adams, Laura C. Coates, M.E. Husni, P. J. Mease
Publikováno v:
Poster Presentations.
Background Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. Ixekizumab (IXE), a monoclonal high affinity antibody that selectively ta
Autor:
Proton Rahman, B. Combe, David H. Adams, Masato Okada, LN Kerr, Catherine L Shuler, B. Kirkham, Mark C. Genovese, P. Nash, Chin Lee
Publikováno v:
Oral Presentations.
Background Tumour necrosis factor inhibitors (TNF-i) have revolutionised the management of psoriatic arthritis (PsA) yet some patients (pts) have an inadequate response (IR) or intolerance. Ixekizumab (IXE), a monoclonal high affinity antibody that s
Autor:
Julie Birt, C.-Y. Lin, Ronald Vender, David H. Adams, Olivier Bénichou, Peter Nash, Arthur Kavanaugh
Publikováno v:
Poster Presentations.
Background Ixekizumab (IXE), a monoclonal high affinity antibody that selectively targets interleukin-17A, was superior to placebo (PBO) in achieving clinical responses and improving health related quality of life (HRQoL) for psoriatic arthritis (PsA